MicroRNAs expression in normal and malignant colon tissues as biomarkers of colorectal cancer and in response to pomegranate extracts consumption: Critical issues to discern between modulatory effects and potential artefacts
Journal article published in 2015 by
María A. Nuñez Sánchez,
Alberto Dávalos 
,
Antonio González-Sarrías ,
Patricia Casas-Agustench,
Francesco Visioli,
Tamara Monedero-Saiz,
Noelia V. García Talavera,
Noelia V. García-Talavera,
María B. Gómez Sánchez,
Carmen Sánchez-Álvarez,
Ana M. García Albert,
Francisco J. Rodríguez Gil,
Miguel Ruiz-Marín,
Francisco A. Pastor Quirante,
Francisco Martínez-Díaz
and other authors.
,
Antonio González-Sarrías ,
Patricia Casas-Agustench,
Francesco Visioli,
Tamara Monedero-Saiz,
Noelia V. García Talavera,
Noelia V. García-Talavera,
María B. Gómez Sánchez,
Carmen Sánchez-Álvarez,
Ana M. García Albert,
Francisco J. Rodríguez Gil,
Miguel Ruiz-Marín,
Francisco A. Pastor Quirante,
Francisco Martínez-Díaz
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
MicroRNAs (miRs) are proposed as colorectal cancer (CRC) biomarkers. Pomegranate ellagic acid and their microbiota metabolites urolithins exert anticancer effects in preclinical CRC models, and target normal and malignant colon tissues in CRC patients. Herein, we investigated whether the intake of pomegranate extract (PE) modified miRs expression in surgical colon tissues vs biopsies from CRC patients.